Holen Sie sich die Stockscreener-App
12.92
1.30%
-0.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$13.09
Offen:
$13.05
24-Stunden-Volumen:
1.48M
Relative Volume:
1.34
Marktkapitalisierung:
$10.76B
Einnahmen:
$3.85B
Nettoeinkommen (Verlust:
$667.93M
KGV:
19.67
EPS:
0.657
Netto-Cashflow:
$142.30M
1W Leistung:
-3.58%
1M Leistung:
-7.12%
6M Leistung:
-11.57%
1J Leistung:
-12.88%
1-Tages-Spanne:
$12.91
$13.06
1-Wochen-Bereich:
$12.91
$13.58
52-Wochen-Spanne:
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
12.92 | 10.90B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Infosys ADR stock jumps over 10% on Wall Street after IT major revises revenue guidance for FY2026 — Details here - Mint
Dr. Reddy’s Labs ADR: Quiet Rally, Firm Fundamentals – Is RDY Still Undervalued? - AD HOC NEWS
HDFC Bank share price drops almost 4% in 2 days after Q3FY26 business update - Mint
What does Infosys ADR stock rally on the NYSE mean for Infosys shares on the NSE, BSE? - livemint.com
Infosys ADR stock jumps over 56% over strong volumes on US stock market today — Details here - livemint.com
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens - Chartmill
Validea's Top Health Care Stocks Based On Peter Lynch12/15/2025 - Nasdaq
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Benzinga
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Sahm
Asian Equities Traded in the US as ADRs Fall in Thursday Trading - 富途牛牛
Kelkar & Mehta: Justice is a constitutional promise: Uphold it by giving alternative dispute resolution a chance - Mint
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History - The Economic Times
Asian ADRs Nudge Higher As Tech And Pets Take The Lead - Finimize
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires New Shares in Full Truck Alliance Co. Ltd. Sponsored ADR $YMM - Defense World
Asian ADRs Dip In The US As Volatility Continues - Finimize
Asian ADRs Kick Off The Week With Broad Gains - Finimize
Is Zoetis Stock Underperforming the Dow? - Barchart.com
US Stock Market today: Dow Jones, Nasdaq, S&P 500 open higher over improving Fed rate cut bets — Details here - livemint.com
Vise Technologies Inc. Makes New Investment in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Migdal Insurance & Financial Holdings Ltd. Sells 20,000 Shares of Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asia’s Biggest US-Listed Stocks Saw Mixed Results Today - Finimize
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - Finviz
Fintech ADRs Dropped While Telecoms And Pharma Firmed Up - Finimize
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):